dc.contributor.author | Hattrem, Magnus Nergård | |
dc.contributor.author | Dille, Morten Johnsen | |
dc.contributor.author | Seternes, Tore | |
dc.contributor.author | Ege, Thorfinn | |
dc.contributor.author | Draget, Kurt Ingar | |
dc.date.accessioned | 2018-03-09T13:16:07Z | |
dc.date.available | 2018-03-09T13:16:07Z | |
dc.date.created | 2017-06-12T20:30:06Z | |
dc.date.issued | 2017 | |
dc.identifier.citation | Clinical pharmacology in drug development. 2017, 7 (2), 168-176. | nb_NO |
dc.identifier.issn | 2160-763X | |
dc.identifier.uri | http://hdl.handle.net/11250/2489850 | |
dc.description.abstract | The first aim of the present study was to evaluate the bioavailability of ibuprofen dispersed in a novel soft chewable formulation compared with a traditional ibuprofen tablet; its second was to map the quality of taste masking and patient product satisfaction. In a phase 1, single-center, open-label, randomized, crossover study, healthy subjects received a soft-chew formulation or a hard tablet (reference), both containing 100 mg ibuprofen. Serial blood samples were collected over 24 hours to assess ibuprofen bioavailability. Taste and satisfaction after chewing the novel formulation 3 or 8 times were evaluated with a questionnaire. The soft-chew formulation showed comparable bioavailability to the reference tablet. The highest peak plasma concentration was observed after 3 chews, and the relative bioavailability was approximately 8% higher compared to 8 chews. The overall flavor was well appreciated, and chewing 3 times was significantly preferred (P = .043) over chewing 8 times. Soft chewable drug formulations may improve compliance and potentially benefit several subpopulations who experience dysphagia. | nb_NO |
dc.language.iso | eng | nb_NO |
dc.publisher | Wiley | nb_NO |
dc.rights | Navngivelse-Ikkekommersiell 4.0 Internasjonal | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc/4.0/deed.no | * |
dc.title | The Relative Bioavailability of Ibuprofen After Administration With a Novel Soft Chewable Drug Formulation | nb_NO |
dc.type | Journal article | nb_NO |
dc.type | Peer reviewed | nb_NO |
dc.description.version | publishedVersion | nb_NO |
dc.source.pagenumber | 168-176 | nb_NO |
dc.source.volume | 7 | nb_NO |
dc.source.journal | Clinical pharmacology in drug development | nb_NO |
dc.source.issue | 2 | nb_NO |
dc.identifier.doi | 10.1002/cpdd.357 | |
dc.identifier.cristin | 1475531 | |
dc.description.localcode | © 2017, The Authors. Clinical Pharmacology in Drug Development published by Wiley Periodicals, Inc. on behalf of The American College of Clinical Pharmacology. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License. | nb_NO |
cristin.unitcode | 194,66,15,0 | |
cristin.unitname | Institutt for bioteknologi og matvitenskap | |
cristin.ispublished | true | |
cristin.fulltext | original | |
cristin.qualitycode | 1 | |